Presentation is loading. Please wait.

Presentation is loading. Please wait.

Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex.

Similar presentations

Presentation on theme: "Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex."— Presentation transcript:

1 Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex England

2 Testicular Germ Cell Tumours Approximately 2000 new cases per year in UK (population 60.000000) 70% of seminomas and 50% of NSGCTs are diagnosed at stage I

3 Considerations in initial management Is a testicular cancer present? Are there metastatses? Is there carcinoma in situ in contralateral testis? If there are bilateral tumours is partial orchidectomy an option?

4 Initial management Widespread malignancy  refer for immediate chemotherapy No evidence of spread  inguinal orchidectomy. Biopsy of contralateral testicle should be considered if there is a high risk of carcinoma in situ eg. small testis (<12ml), and in patients < 30 years. SJ Harland. Eur Urol 1993 n= 89. 13% pts had CIS in contralateral testis. Increased risk of CIS in clinically atrophic testes, but NOT in maldescent. Pts found to have CIS were younger < 30 Complete post – op staging, CT chest/abdo/pelvis Post –op tumour markers if raised pre-op. Should fall according to half life – (4-6 days for AFP, 24 hours for HCG )

5 Points to consider in managing stage 1 germ cell tumours Seminomas spread predictably, firstly to the para- aortic lymph nodes and subsequently to the supra- diaphragmatic LNs and on to other metastatic sites. NSGCT spread more randomly with blood borne mets occuring earlier than with seminoma NSGCT produce AFP and/or HCG in 75% of cases Seminomas produce HCG in only 25% of cases LDH is non-specific. In our series of 494 patients who relapsed on surveillance over a 10 year period, the LDH alone did not identify any of these.

6 Management of carcinoma in situ 50% of patients with CIS will develop invasive tumours within 5 years from diagnosis. Low dose XRT (20 Gy in 10#s) to the testis eradicates CIS, relapses with lower doses Leydig cell function increasingly impaired at doses > 17 Gy Long term hormone replacement therapy may be necessary

7 Possible prognostic factors for stage 1 germ cell tumours SEMINOMAS 1.Size of tumour (J Clin Onc 2002, Warde et al) 2.Invasion into the rete testis 3.Age 4.Small vessel invasion 5.Histological subtype – classical vs anaplastic 6.DNA ploidy status 7.Mitotic count 8.DNA S-phase % 9.Syncitiotrophoblasts 10.Degree of lymphocytic infiltration of primary tumour 11.Expression of HCG and low MW keratin on immunohistochemistry TERATOMAS 1.Lymphovascular invasion 2.Embryonal ca histology in primary tumour 3.MIB- 1 monoclonal ab – marker of proliferative activity 4.Mitotic count

8 Options for management of stage I Seminomas Adjuvant radiotherapy Adjuvant chemotherapy Surveillance

9 1980’s Management of stage I seminoma 20% will recur after orchidectomy 90% relapse in para-aortic nodes Traditionally adjuvant treatment with radiotherapy to para- aortic and ipsilateral iliac nodes in a “dog leg” field. (28- 30 Gy)

10 Late Morbidity from Radiotherapy Second Cancers Cardiac events Peptic ulceration Infertility

11 Relative risks for second primary cancers (NB. RR of contralateral testis ca is 35.7!) 1.725Colon 1.316Rectum 2.216Kidney 1.847Other skin 1.35Melanoma 1.042Lung 1.121Prostate 2.137Bladder 2.115Pancreas 1.924Stomach 2.313Leukaemia 1.5337All sites RRn


13 Strategies to reduce radiotherapy morbidity Reduction of radiation field size MRC TE10 478 patients randomised to traditional dog-leg or para-aortic radiotherapy Reduction in dose MRC TE18 625 patients randomised to 30 Gray in 15 # over 3 weeks or 20 Gray in 10 # over 2 weeks

14 MRC TE10 (Fossa et al 1999) Survival at 3 years, 99% for PA vs 100% for DL RFS 96% PA vs 96.6% DL Acute toxicity ( nausea, vomiting, leukopaenia) was less frequent and less severe in PA group Within the first 18/12 of F/U the sperm counts were significantly higher after PA than after DL radiotherapy. CONCLUSION: Adjuvant radiotherapy confined to the paraaortic LNs is associated with decreased haematologic, GI and gonadal toxicity, but with a higher risk of pelvic recurrence compared with dog-leg radiotherapy.

15 MRC TE 18 (Jones et al 2001 & 2005) At median follow-up of 4 years 2 year relapse free survival 97.7% after 30Gy 97% after 20Gy Better Quality of Life scores for acute effects in lower dose arm Therefore: Standard radiotherapy for stage 1 seminoma should be: 20 Gy in 10 # over 2 weeks to para-aortic strip unless previous inguino/pelvic/scrotal surgery when “dog- leg” field.

16 Can chemotherapy replace radiotherapy for stage 1 seminoma ? TE19 / EORTC 30982 Randomised comparison of single agent carboplatin AUC 7 with radiotherapy in adjuvant treatment of stage 1 seminoma following orchidectomy. carboplatin n=1447 30Gy/15#s Radiotherapy 20Gy/10#s

17 TE 19 Radiotherapy vs carboplatin : Relapse Free Rate RFR at 2 years at 3 years R96.7% (95%, 98%)95.9% (94%, 97%) C97.7% (96%, 99%)94.8% (93%, 96%) Absolute difference R - C =-1.0% (-2.5%, 0.5%)1.1% (-1.0%, 3.2%) HR based CI for difference R – C =0.9% (-0.5%, 3.0%)1.1% (-0.6%, 3.7%)

18 Results of TE19 / EORTC 30982

19 Late Morbidity from Chemotherapy Infertility Second Tumours Cardiovascular damage

20 Prognostic Factors for seminomas on surveillance ( Warde et al 2002) 121 of 638 patients relapsed at a median follow up of 7 years (Relapse free survival 82%) On multivariate analysis: Tumour size 4cm, hazard ratio 2 Invasion of the rete testis, hazard ratio 1.7 5 year recurrence rate Both risk factors 32% Single risk factor16% No risk factors12%

21 Post orchidectomy surveillance vs carboplatin for stage 1 seminoma – Spanish germ cell cancer cooperative group; Ann oncol 2003 N = 203 60 pts with tumour >4cm or lymphovascular invasion given 2 x carboplatin 143 pts with no risk factors put on surveillance 5 yr DFS 83.5% in surveillance pts and 96.6% in carbo grp. All salvaged with 3 or 4 cycles of BEP 5 year OS 96.7%. Cause specific survival 100%

22 Conclusion on management of stage 1 seminomas Almost 100 % of patients with stage 1 seminoma are cured regardless of approach chosen as post orchidectomy therapy. Adjuvant radiotherapy or chemotherapy are both as effective at reducing relapse rates. However with a relapse rate of 15-20%, and a 5 year survival of 97.7%, surveillance may be considered an alternative “treatment” option. Identification of prognostic factors for relapse on surveillance will allow clinicians to recommend the most appropriate therapy for individual patients. Current recommendations – tumours 4cm and presence of rete testis invasion – RR 35%  offer adjuvant therapy

23 Management Options for Stage 1 Non- seminomatous germ cell tumours Surveillance RPLND Adjuvant chemotherapy

24 Surveillance for Non- seminomatous germ cell tumours relapse rate Overall 30% Lymphovascular invasion<40% No risk factors10-15%

25 Surveillance programme MVH - NSGCTs Markers currently HCG, AFP and LDH Follow up for 10 years Month 123456789101112182436 OPD XXXXXXXXXXXXXXX CXR XXXXXXXXXXXXX Markers xx XXXXXXXXX CT Chest/ abdo/ pelvis XX

26 Advantages of Surveillance for Low risk NSGCT >80% avoid any chemotherapy or RPLND >80% avoid risk of 2nd tumours >80% avoid risk of cardiovascular damage >80% avoid risk of infertility

27 Disadvantages of surveillance for NSGCT More frequent clinic visits and blood tests Greater diagnostic radiation (10 body CT scans induces 1% 2nd tumours) Anxiety of follow -up Concern about non-attendance

28 MRC TE08 trial of surveillance intensities Currently a wide variation in the intensity of surveillance programs between hospitals Concern about high levels of radiation produced by CT scans Alternative methods need to be found to determine relapse during surveillance Frequency of CT scans needs to be kept to a minimum

29 Study Design Histologically confirmed Stage I NSGCT Randomise 5 CT scans Chest and abdomen CT at 3 months Chest and abdomen CT at 6 months Chest and abdomen CT at 9 months Chest and abdomen CT at 12 months Chest and abdomen CT at 24 months 2 CT scans Chest and abdomen CT at 3 months Chest and abdomen CT at 12 months 3:2 randomisation in favour of 2 CT arm

30 Lack of value of chest CT scans in surveillance of Stage I NSGCT 168 patients42 (25%) relapsed 8/42 (19%) intrathoracic relapse All 8 had abnormal CXR at relapse 7/8 also had elevated AFP and or HCG (Harvey et al Annals Oncol 13: 237-42, 2002)

31 183 stage 1 GCT on surveillance: Initial Presenting Factors among 52 relapses (Francis et al EJC 2000) SymptomsTumour Markers Radiology(total/no. NSGCT/no. seminoma) 3/2/1 24/21/3 18/12/6 15/8/7 3/3/0 4/3/1 3/3/0

32 Adjuvant BEP chemotherapy for high risk NSGCT (Cullen et al 1996) 2 courses Bleomycin 30,000 units day 2, 8, 15, Etoposide 120 mg/m2 days 1-2, Cisplatin 50 mg/m2 day 1&2 Reduces risk of relapse to <3%

33 MRC Trial TE22: Study of FDG PET in the prediction of relapse in patients with high risk stage 1 NSGCT 108 patients registered by 13.12.2004 78/96 (81%) PET scans negative, 77/78 chose surveillance Expected relapse free rate for high risk ~60% at 2 years Anticipated relapse free rate for PET –ve patients ~90% at 2 years (90%CI >80%) Interim analysis 12 month relapse free rate in 77 PET –ve patients 65% (90% CI 53-74%) at 2 years at best 70% Trial closed 18.1.05

34 Comparison of management policies for NSGCT Surveillance Low risk RPLNDAdjuvant BEP Relapse rate<20% 5-23%<3% Require chemo<20% 5-23%100% Require RPLND< 5% 100% <1%

35 Comparison of costs per life saved for managing stage 1 germ cell tumours (Francis et al EJC 2000) SurveillanceRPLNDAdjuvant chemotherapy £6126£7672£5851

36 Management of Stage 1 Testicualr Germ Cell tumours Many surgeons do orchidectomies, Only a few oncologists should specialise in managing GCT patients Patients should be made aware of the different management options Deciding which option depends upon histology, prognosis, geography, personality, reliability, bias of the doctor, but most importantly the patient

37 Life insurance for patients treated for germ cell tumours Time withoutTime to standardExtra/£1000 yr3-4Extra year 5-6 Seminoma stage11 year4 years£5 Non-seminoma stage 1 1 year6 years£10£5 Stage 2 A/B2-3 years9 years£10£5 Stage 2 B, stage 33 years9 years£15£10 Stage 4, intermediate and poor risk 3-4 years9 years£20£15 Temporary loading usually lasts 3-6 years Provided by Graham Jones Underwriting Development Product Management & Development - Protection Direct line: 01793 505736 (internal: 5736) Email:

38 Factors for Research Prognostic factors to more accurately define those requiring treatment : eg. Compare by comparative genomic hybridization and expression micoarray analysis relapses versus non relapses Reduce diagnostic radiation by comparing MRI with CT scans To better understand factors increasing incidence of germ cell tumours To better understand relationship of 12p isochromosome and Kit with germ cell tumours

39 STROMAL TUMOURS OF THE TESTIS Leydig, Sertoli cell, Granulosa cell or combined tumoursLeydig, Sertoli cell, Granulosa cell or combined tumours 3% of testis tumours, 10% bilateral3% of testis tumours, 10% bilateral Derive from cells making hormonesDerive from cells making hormones Mean age 36 yearsMean age 36 years 10% metastasise – cannot currently be predicted from histopathology of the primary tumour10% metastasise – cannot currently be predicted from histopathology of the primary tumour testosterone, oestradiol and androstenedione are markers (AFP and hCG are not) testosterone, oestradiol and androstenedione are markers (AFP and hCG are not) Resistant to conventional chemotherapy and radiotherapy.Resistant to conventional chemotherapy and radiotherapy.

40 SURVIVAL FOLLOWING RPLND FOR STROMAL TUMOURS OF THE TESTIS ACCORDING TO PATHOLOGICAL STAGE. 0.00 0.25 0.50 0.75 1.0 0.025 50 75100 Time (months) Survival Stage I Stage II.


42 Would surveillance alone be an option?

43 Curr opin oncol 2004 n= 394 stage I seminomas, 301 stage I NSGCTs, post orchidectomy 1984- 2002. 22% relapse rate – 17% seminomas, 29% NSGCTs. Median time to relapse 13 months for seminomas with 49% relapsing in first year, 5 months for NSGCT, 80% relapsing in first year. 54% of NSGCTs with vascular invasion relapsed and 38% of the seminomas 32% of NSGCTs with embryonal ca relapsed. 90% of relapses detected as routine examination, remaining 10% at patients initiative – treated appropriately with surgery/chemo/radiation 10 deaths in F/u, not related to GCT Os 98.6%, cause specific survival 100%





48 Surveillance programme MVH - seminomas CXR & markers performed at each clinic visit. Year 2 OPD every 2/12, Year 3 every 3/12, year 4 every 4/12, years 5 and 6 every 6/12. Yearly thereafter to 10 years. Lifetime follow-up if had XRT. Month 1234567891012182436 OPD XXXXXXXXXXXXXX CXR XXXXXXXXXXXXXX Markers XXXXXXXXXXXXXX CT abdo/ pelvis XXXX

49 Management of stage I NSGCT Relapse rate after orchidectomy alone – 25% Vascular or lymphatic invasion relapse rate – 40% Surveillance – low risk patients (85% cure rate surgery alone) 2 x BEP – in high risk patients with vascular or lymphatic invasion reduces relapse rate to 1% Prophylactic RPLND J Urol 2000 – group of high risk stage I teratomas, relapse risk 35-40% - RPLND reduced relapse risk to 23%. Comparable group given BEP x 2 – risk of relapse 3-4%. Good risk patients on surveillance with a 15-20% risk of relapse - RPLND reduces relapse risk to 5%


51 Management of Stage IIA and B seminoma Radiotherapy 30Gy in 15 fractions

52 Stage II NSGCT Ongoing debate  ?PRLND alone vs neoadjuvant chemo followed by surgery. German trial n=187. No difference in OS but in suregery alone group, significantly higher loss of ejaculation Oldenberg et al n=87, stage II NSGCT undergoing RPLND 1990-2000. All patients had masses < 2cm on imaging. Viable tumour found in 33% (26% mature teratoma, 7% malignant tumour), 67% fibrosis/necrosis. –No clinical/serological parameters were predictive of histopath findings. CONCLUSION: RPLND recommended for all patients with masses < 2cm because of high rate of viable tumour found

53 Testicular germ cell tumours – Professor Rustin – MVH Cancer Centre

54 Testicular germ cell tumours Professor Rustin – MVH Cancer Centre



57 Testicular Germ Cell tumours Professor Rustin Mount Vernon Hospital Cancer Centre


59 1-1.5% of male neoplasms Most common tumour in men aged 20-35 yrs. Incidence has doubled in last 20 years One of the few solid tumours which is completely curable even after it has metastasized with an overall survival of 90% 70% of seminomas and 50% of NSGCTs are diagnosed at stage I

60 Pathological classification of testicular cancers Seminoma Spermatocytic seminoma TeratomaNon-seminomatous germ cell tumour Teratoma Differentiated (TD)Mature teratoma Malignant teratoma intermediate (MTI) Embryonal carcinoma with teratoma (teratocarcinoma) Malignant teratoma undiffrentiated (MTU) Yolk sac tumour, embryonal carcinoma Malignant teratoma trophoblastic (MTT) Yolk sac tumour; choriocarcinoma






66 RMH Staging I – No evidence of disease outside the testis IM – As above but persistently raised tumour markers II – Infradiaphragmatic nodal involvement IIA – max diameter <2cm IIB- max diameter 2-5cm IIC – max diameter 5-10cm IID – max diameter >10cm III – Supra and infradiaphragmatic node involvement Abdominal nodes a,b,c, as above, Mediastinal nodes M+, Neck nodes N+ IV – Extralymphatic metastases. Lungs: L1 - 2cm. Liver involement H+. Other sites specified.




70 Prognostic Factors for seminomas on surveillance

71 n=638 (seminomas), F/U 7 years, 121 relapses – 5 year RFR 82% On univariate analysis: tumour size – RFR 4cm 76% (p=0.003) Rete testis invasion – RFR 86% (absent), 77% (present) p=0.003 Presence of small vessel invasion – RFR 86% (absent), 77% (present) p= 0.038

72 Prognostic factors investigated in seminomas




Download ppt "Management Strategies for Stage I germ cell tumours Professor Gordon J S Rustin Director of Medical Oncology Mount Vernon Hospital Northwood, Middlesex."

Similar presentations

Ads by Google